Recent Quotes

My Watchlist

Indicators

G1 Therapeutics, Inc. - Common Stock (NQ: GTHX )

7.150 UNCHANGED

Last Price Updated: 4:00 PM EDT, Sep 17, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	7.150
Bid (Size)	7.140 (212)
Ask (Size)	7.180 (13)
Prev. Close	7.150
Today's Range	7.150 - 7.150
52wk Range	1.442 - 7.190
Shares Outstanding	42,705,532
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer

September 18, 2024

From G1 Therapeutics

Via GlobeNewswire

Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period

September 05, 2024

From G1 Therapeutics

Via GlobeNewswire

Performance

YTD	+129.90%	+129.90%
1 Month	N/A	N/A
3 Month	N/A	N/A
6 Month	+222.07%	+222.07%
1 Year	+139.93%	+139.93%

More News

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GVP, PETQ, GTHX on Behalf of Shareholders

August 15, 2024

From Halper Sadeh LLC

Via GlobeNewswire

Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?

August 07, 2024

Via InvestorPlace

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP)

August 15, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

G1 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of G1 Therapeutics, Inc. - GTHX

August 09, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders

August 09, 2024

From Halper Sadeh LLC

Via GlobeNewswire

August 08, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights

August 08, 2024

From G1 Therapeutics

Via GlobeNewswire

Dow Tumbles Over 200 Points; CVS Health Cuts Profit Forecast

August 07, 2024

Via Benzinga

Crude Oil Jumps Over 3%; Upstart Shares Spike Higher

August 07, 2024

Via Benzinga

Nasdaq Jumps 250 Points; Disney Earnings Beat Estimates

August 07, 2024

Via Benzinga

GTHX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of G1 Therapeutics, Inc. Is Fair to Shareholders

August 07, 2024

From Halper Sadeh LLC

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

August 07, 2024

Via InvestorPlace

Pharmacosmos Group to Acquire G1 Therapeutics

August 07, 2024

From G1 Therapeutics; Pharmacosmos

Via GlobeNewswire

G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

July 25, 2024

From G1 Therapeutics

Via GlobeNewswire

G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025

July 15, 2024

Via InvestorPlace

Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble

July 10, 2024

Via InvestorPlace

Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday

June 25, 2024

Via Benzinga

Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears

June 24, 2024

Via InvestorPlace

Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts

June 24, 2024

Via InvestorPlace

Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge

June 24, 2024

Via Benzinga

Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday?

June 24, 2024

Via Benzinga

Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?

June 24, 2024

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

June 24, 2024

Via InvestorPlace

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.